Treating Multiple Myeloma and Ovarian Cancer With Liposomal Doxorubicin

Liposomal Doxorubicin Uses for Multiple Myeloma

Multiple myeloma is cancer that begins in plasma cells (a type of white blood cell). Myeloma begins when a plasma cell becomes abnormal. The abnormal cell makes copies of itself by dividing again and again, making more and more abnormal cells. The abnormal plasma cells are myeloma cells.
Myeloma cells:
  • Make antibodies called M proteins
  • Collect in the bone marrow
  • May crowd out normal blood cells
  • Collect in the solid part of the bone.
The disease is called "multiple myeloma" because it affects many bones. If myeloma cells collect in only one bone, the single mass is called a plasmacytoma. Multiple myeloma is the most common type of plasma cell tumor.
Liposomal doxorubicin is approved for use in combination with bortezomib (Velcade®) to treat multiple myeloma in people who have not yet received bortezomib treatment but have tried at least one other type of treatment.

Liposomal Doxorubicin Uses for Ovarian Cancer

Ovarian cancer is a disease in which cancerous cells form in the tissues of the ovaries. Women with this type of cancer have many treatment options available to them, including:
Many women receive more than one type of treatment.
Liposomal doxorubicin is approved for treating ovarian cancer in women whose cancer has progressed despite treatment with platinum-based chemotherapy (any medication that has "platin" in the name).
The Zen of Cancer Caregiving - Recharge Your Batteries!

Liposomal Doxorubicin Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.